Latest from MSKCC

Alexander E. Drilon, MD, discusses the data with LOXO-292 thus far and the promise for this agent in patients with RET alterations.

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the synergy between lenvatinib and pembrolizumab in the treatment of patients with endometrial cancer.

Jonathan E. Rosenberg, MD, discusses the promise of enfortumab vedotin in patients with bladder cancer who previously received a checkpoint inhibitor, and reflects on the rapid pace of change in the urothelial cancer landscape.

Investigators are evaluating the potential of LOXO-292, an oral small molecule inhibitor of RET signaling, to improve outcomes in patients with RET fusion–positive non–small cell lung cancer, medullary thyroid cancer, and other tumors.

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses unmet needs and treatment challenges for patients with advanced endometrial cancer.

Anthony R. Mato, MD, MSCE, discusses the next steps for umbralisib and the biggest challenges still facing patients with chronic lymphocytic leukemia.

Sham Mailankody, MBBS, discusses current treatment options and shifting preferences, especially toward triplet combinations, as well as emerging immunotherapy treatment options in multiple myeloma.

An assay for nuclear-localized androgen receptor splice variant 7 protein in circulating tumor cells identified patients with metastatic castration-resistant prostate cancer who had better outcomes from treatment with taxanes, and those who did better with androgen receptor-signaling inhibitors.